NCI UNC Project ESCC
NCT03206125 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 648
Last updated 2020-05-20
Summary
Background:
Esophageal cancer is a common cause of cancer deaths. Most cases of this cancer are esophageal squamous cell carcinoma (ESCC). Many of these cases come from two parts of the world with high-risk. One of these is in East Africa and include the country of Malawi. Researchers want to learn what factors explain the high risk there so we can understand better what causes this cancer in people everywhere.
Objective:
To learn more about causes and outcomes of esophageal squamous cell carcinoma using Malawi because of the large number of cases in that country.
Eligibility:
Adults at least 18 years old who have ESCC and live in a certain region of Malawi
Adults in the same age group and location who do not have ESCC
Design:
Participants will be screened at a hospital in Malawi.
Participants will have a 1-hour interview. They will answer questions about:
Demographics (age, ethnicity, education)
Place of residence
Medical history and family medical history
Drug, alcohol, and tobacco use
Hot beverage consumption
Indoor air pollution
Occupation
Food habits
Farming
Gastrointestinal health
Participants will have their teeth and fingernails examined.
Participants will be asked to give samples of blood, urine, saliva, toenails, and for the cancer cases, a small piece of their tumor.
Participants will have 4 phone calls a year for 2 years to ask about their health....
Conditions
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Christian Abnet, Ph.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-08-01
- Primary Completion
- 2020-05-15
- Completion
- 2020-05-15
Countries
- Malawi
Study Locations
More Related Trials
-
Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus
NCT00766480 ·Status: UNKNOWN ·Phase: NA
-
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
NCT05426850 ·Status: UNKNOWN
-
Esophageal Cancer Risk Registry
NCT00260585 ·Status: RECRUITING
-
Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients
NCT02221245 ·Status: TERMINATED
-
Precisely Estimation of the Prognostic Value of Lymph Node in ESCC
NCT04764240 ·Status: COMPLETED
-
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
NCT03223662 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital
NCT01981876 ·Status: COMPLETED
-
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT05659251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus
NCT01225523 ·Status: COMPLETED ·Phase: PHASE1
-
Esophageal Cancer Genetics Studies
NCT00341276 ·Status: COMPLETED
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
NCT02645864 ·Status: COMPLETED ·Phase: PHASE1
-
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
NCT06642506 ·Status: ACTIVE_NOT_RECRUITING
-
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
NCT04666090 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
NCT06241066 ·Status: COMPLETED
-
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
NCT06010212 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.
NCT01248299 ·Status: TERMINATED ·Phase: PHASE2
-
Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy
NCT06061263 ·Status: UNKNOWN
-
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
NCT05833594 ·Status: RECRUITING
-
Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction
NCT04229524 ·Status: UNKNOWN ·Phase: NA
-
Detection of Circulating Tumor Tells as The Guidance of the Neoadjuvant Chemotherapy of Esophageal Cancer
NCT03005314 ·Status: UNKNOWN ·Phase: NA
-
Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)
NCT00915850 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial
NCT01044420 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569242 ·Status: COMPLETED ·Phase: PHASE3
-
Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC
NCT04759235 ·Status: UNKNOWN